BioSpace News Archive

Halberd Corporation’s Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer reviewed and accepted for publication, but has not yet been published.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for December 2022.

IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST.

SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) for SPVN06, its lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent inherited retinal disease (IRD).

Adaptive Biotechnologies Corporation today announced the launch of its clonoSEQ® Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL).

Citius Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for denileukin diftitox (“I/ONTAK” or “E7777"), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Haystack Oncology today announced the appointment of Joel Kaufman as Chief Financial Officer.

WISE Cortical Strip is the first cortical strip embedding the electrodes in a highly compliant thin film of silicone to receive FDA clearance.

Theriva Biologics announced that Company’s Management will participate in the following upcoming investor conferences in December.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.